Skip to main content
. 2018;19(2):331–335. doi: 10.22034/APJCP.2018.19.2.331

Table 2.

Comparison of Patients According to CD20 Expression

CD20 positive. n-48 patients CD20negative .n-6 patients
Mean age 55.3 53.6
Gender
 Males 29(60%) 5(83.3%)
 Females 19(40%) 1(16.6)
RIPI II/III II/III
Initial regimen
 R-CHOP 39(69.6%) 5(83.3%)
 RCVP 7(13%) 1(16.7%)
 REPOCH 2(3.7%)
Response to First line treatment
 CR 26(48%) 2(33%)
 Relapsed 24(50%) 2(33%)
 Refractory 24(50%) 4(66.6%)
Salvage chemo
 RDHAP/DHAP 8(33.3%) 3(50%)
 ICE 5(21%) 1(16.6%)
 Others 4(16.6%) 2(33.3%)
Site of relapse
 Lymph nodes 11(46%) 0
 GIT 4(14.6%) 2(100%)
Response to salvage Chemo
 Complete response 12(50%) 2(33%)
 Refractory 28(44.4%) 4(14.3%)
 Median DFS(Months) 12 9
 Median OS (Months) 17.5 13